Ocular Therapeutix (OCUL) Tops Q2 EPS by 16c

Ocular Therapeutix (NASDAQ: OCUL) reported Q2 EPS of ($2.10), $0.16 better than the analyst estimate of ($2.26). Revenue for the quarter came in at $97 thousand versus the consensus estimate of $100 thousand.

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.

You May Also Be Interested In

• SanDisk stock target lifted by Citi on continued demand strength
• Rank One Computing (ROC) Reiterated at Buy by Benchmark Post ZTC Acquisition
• Travere Therapeutics (TVTX) PT Raised to $65 at Guggenheim